- Back
- Back
- Back
- Back
- Back
- Back
- Back
- Back
- Back
- Back
Last Updated on 06/07/2026 by Sarah Sarsby
The latest NHS Supply Chain (NHSSC) supplier webinar, held on 1 July 2026, provided further detail on the future Single Transacted National Price (STNP) programme, alongside updates on value-based procurement (VBP), clinical evidence requirements, and sustainability.
The webinar also reinforced expectations around value-based procurement and robust clinical evidence to support procurement decisions.
NHSSC provided further detail on its STNP programme, which forms part of the Commercial Transformation Programme’s Pricing Simplification project and will be introduced progressively as part of NHS Supply Chain 2030.
The proposed model will see all transacted frameworks move towards a single national buy price for each product, supported by new national value mechanisms designed to aggregate commitments across the NHS and maximise value. Centrally funded customers would access the same national sell price, removing customer-specific pricing tiers, banding, and additional discounts, while price variation would remain only for non-centrally funded customers where centrally determined margins apply.
Suppliers would be expected to support the transition by moving away from negotiating customer-specific discounts and rebates for NHS Supply Chain sales. Incentive schemes would instead be managed centrally, while frameworks unable to support STNP may, by exception, transition to a non-transacted (direct) procurement route.
NHSSC said pricing simplification aims to improve transparency, reduce administrative complexity, and create a more predictable pricing environment, allowing both suppliers and NHSSC to focus more on innovation, product development, and delivering value to the NHS.
Implementation will be gradual. In the short term, the National Value Programme will continue to optimise existing National Pricing Matrices (NPMs), including removing some where appropriate. Over time, new pricing mechanisms will replace NPMs and Market Basket Management Strategies (MBMS) as frameworks are renewed, enabling full adoption of STNP. NHSSC also confirmed it does not intend to return to commitment discounts or direct rebates as part of the new approach.
Value-based procurement (VBP) remains a key focus for NHSSC. As outlined in BHTA’s previous article on the new NHS value-based procurement guidance, suppliers are increasingly expected to demonstrate value across six domains: social value, efficiency, patient and staff outcomes, supply chain resilience, purpose, and whole-life cost.
The webinar highlighted a significant change in how supplier responses are evaluated. Rather than relying on pass/fail or yes/no assessments, procurement exercises will increasingly use scored, text-based responses to assess the strength of each submission. Meeting the minimum requirement is now considered the starting point, with suppliers expected to explain and evidence how their solution delivers greater quality and value than competing offers.
NHSSC also confirmed that VBP extends beyond contract award. Commitments made during the procurement process become part of the long-term offer, with value monitored and measured throughout the life of the contract. The same value criteria may also be applied during call-off competitions and further competitions under framework agreements.
NHSSC reiterated that clinical evidence plays a vital role in supporting product assessments and NHS procurement decisions.
Suppliers were reminded that evidence should, wherever possible, be published in peer-reviewed journals. Where evidence is based on case studies or case reports, NHSSC said research from the UK or comparable healthcare systems, including France, Denmark, Canada, and Australia, is particularly valuable. Larger international studies can also strengthen submissions where they have been published internationally or presented at recognised conferences.
NHSSC also highlighted guidance from the National Institute for Health and Care Excellence (NICE), which states that clinical evidence should be relevant to the evaluation, transparently reported, systematically assembled, and analysed using robust methods that minimise bias. NICE also recommends clearly justifying the selection of outcomes, resource use, and costs within the evidence base.
Suppliers were encouraged to focus evidence on the specific product being submitted, move beyond marketing claims, clearly explain the problem the product is intended to solve, and use evidence relating to the current product rather than previous generations. NHSSC also advised against relying on generic therapy-area evidence or evidence from unrelated products to support claims.
The webinar concluded with a brief update on sustainability requirements.
NHSSC confirmed it is reviewing NHS England’s updated 2027 Net Zero supplier requirements to determine how they will be implemented operationally. No further detail was provided, although suppliers were advised that further updates will follow as this work progresses.
